ImmunityBio, Inc.

Healthcare

NASDAQ:IBRX · NASDAQ Global Select

Market Cap $7.44B Beta 0.10 P/E (TTM) -8.5

$7.10 -1.39%

-$0.10 today

52W Low $1.95High $12.43

Vol 8.58M · Avg 17.36M

EPS (TTM)-$0.83

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+131.27%

Period High

$11.55

Period Low

$1.98

Latest

$7.10

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Liquidia Corporation

NASDAQ:LQDA

$6.33B

Cogent Biosciences, Inc.

NASDAQ:COGT

$5.66B

Denali Therapeutics Inc.

NASDAQ:DNLI

$3.44B

Beam Therapeutics Inc.

NASDAQ:BEAM

$2.99B

Arcus Biosciences, Inc.

NYSE:RCUS

$2.40B

89bio, Inc.

ETNB

$2.20B

Galapagos N.V.

GLPG

$1.84B

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

$1.75B

Viridian Therapeutics, Inc.

NASDAQ:VRDN

$1.47B

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

$1.41B

What is the latest IBRX filing?

The latest filing shown is 4 dated Jun 10, 2026.

How many recent filings does IBRX have?

Intrinsic Alpha currently shows 20 recent filings for IBRX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.